Daniel DeAngelo, MD, PhD, is an associate professor of medicine at Harvard Medical School and a physician within the Adult Leukemia Program at Dana-Farber Cancer Institute in Boston, MA.
Dr DeAngelo earned his MD and PhD in molecular genetics from Albert Einstein College of Medicine in 1993, followed by residency in internal medicine at Massachusetts General Hospital. He served a clinical fellowship in hematology and oncology at the Brigham and Women’s Hospital and Dana-Farber Cancer Institute, where he joined the staff in 1999.
His work focuses on optimizing therapy for adult leukemias, myelodysplastic syndromes and myeloproliferative disorders. He serves on the leukemia core committee for the Cancer and Leukemia Group B (CALGB) and is principal and co-investigator of several ongoing clinical studies. Dr DeAngelo is actively involved in a number of professional societies such as the American Society of Hematology and the American Society of Clinical Oncology. In addition, he serves as a member of the NCCN CML and ALL guidelines committee.
Mark Levis, MD, PhD, is a medical oncologist from Baltimore, MD. He is affiliated with Johns Hopkins Hospital and is an associate professor of oncology at Johns Hopkins University School of Medicine.
Dr Levis received his medical training from the University of California, San Francisco School of Medicine, where he also earned his PhD in Biochemistry. He completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology.
Dr Levis is a specialist in ALL/CLL, AML/CML and myelodysplastic syndromes. He is clinical scholar of the Leukemia and Lymphoma Society, as well as a member of the American Society of Hematology, the American Society of Clinical Oncology and the European Hematology Association. He also serves on the Oncology Drug Advisory Committee and earned numerous awards, such as the Daniel Nathans Research Award from Johns Hopkins University, the Osler Housestaff Teaching Award, and the Advanced Clinical Research Award from the American Society of Clinical Oncology.
Sabina Chiaretti MD, PhD is an Assistant Professor in the Department of Cellular Biotechnologies and Haematology at the Sapienza University in Rome, Italy.
Dr Chiaretti completed her medical degree and residency at the Sapienza University, and her PhD at the Sapienza University and the Dana-Farber Cancer Institute in Boston, USA.
Her main clinical focus is on the management of adult ALL.
Naval G. Daver, MD, is an associate professor in the Department of Leukemia, Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center, Houston, TX.
Dr Daver received his MD from Grant Medical College and Sir J.J. Group of Hospitals in Mumbai, India. He then completed a Research Fellowship, Clinical Residency and Clinical Fellowship in succession at Baylor College of Medicine, Houston, TX. He serves on numerous Institutional Committees, including the MD Anderson Department of Leukemia Fellowship Steering Committee.
With a strong research profile, Dr Daver is involved in a range of clinical trials and research, including that looking into immunotherapy, epigenetics and the potential of minimal residual disease monitoring. He also shares the latest hematology-oncology news on his Twitter.
Dieter Hoelzer, MD, PhD, is a professor of Internal Medicine at the University of Frankfurt, Frankfurt, Germany.
Prof Hoelzer studied medicine at the Universities of Münster, Munich, Vienna and Freiburg. He received his PhD in Clinical Physiology at University of Ulm. He became professor of medicine and head of the Department of Hematology/Oncology, Rheumatology, and Infectious Diseases at the University of Frankfurt in 1984. He serves as director of the hematological-oncological private practice, ONKOLOGIKUM, in Frankfurt.
Prof Hoelzer is a specialist in acute leukemias and is also involved in stem cell research. He is the recipient of several awards for cancer research and therapy, including those of the German Cancer Society, the “Deutsche Krebshilfe”, the Johann-Georg-Zimmermann Prize and the San Salvatore Award. Moreover, he is a member of several Advisory Boards and Visiting Professor at numerous universities worldwide.
Marina Konopleva MD, PhD is a Physician-Scientist and Professor in the Departments of Leukemia and Stem Cell Transplantation at the MD Anderson Cancer Center at the University of Texas, Texas, USA.
Dr Konopleva completed her MD at 1st Pavlov Medicinal Insitute in St. Petersburg, Russia, and her PhD in Experimental Haematology at the Federal Institute of Haematology and Blood Transfusion in St. Petersburg.
Her laboratory is studying novel agents in AML and ALL.
Bob Löwenberg, MD, PhD, is a professor of hematology at Erasmus University Medical Center in Rotterdam, the Netherlands, and is the editor-in-chief of Blood.
Prof Löwenberg received his medical training at University of Groningen and carried out postgraduate research at Erasmus University. He is the founder and chair of the European HOVON Leukemia Cooperative group and elected member of the Royal Academy of Sciences and Arts in the Netherlands. He has served on several advisory committees and is on the editorial board of several international journals, including The New England Journal of Medicine.
His research is concerned with the treatment and the pathobiology of leukemia, lymphoma and hematopoietic stem cell transplantation. He has received various international awards for his scientific contributions, such as the Jacqueline Seroussi Memorial Foundation for Cancer Research Award.
Richard Stone, MD, is the chief-of-staff and program director of adult leukemia at the Dana-Farber Cancer Institute, Boston, MA, USA.
Dr Stone obtained his MD from Harvard Medical School in 1981 and undertook his medicine residency training at Brigham and Women’s Hospital and his hematology-oncology fellowship at the Dana-Farber Cancer Institute.
He is nationally recognized for his translational and clinical research concerning blood and bone marrow malignancies, including acute leukemia, myeloproliferative disorders and myelodysplastic syndrome.
He currently serves on the Medical Oncology Board of the American Board of Internal Medicine, and is vice chair of the Leukemia Core Committee for the national cooperative trials group Cancer and Leukemia Group B. Moreover, he has been a member of Scientific Advisory Board at Actinium Pharmaceuticals since May 2017.
Marion Subklewe, MD, is the associate professor for hematology, oncology and cellular immunotherapy, head of flow cytometry at the Laboratory of Leukemia Diagnostics and head of Translational Cancer Immunology, LMU at Gene Center Munich.
Prof Subklewe’s studied at the RWTH Aachen University and the University of Cologne, Germany, before undertaking her postdoctoral fellowship at the Rockefeller University, New York.
Prof Subklewe has recieved many awards, the most recent being the M4-Award 2015: Startup support for the development of a novel multispecific antibody derivative and the ASH Abstract Achievement Award 2015: Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE Antibody Construct (AMG 330) Mediated Cytotoxicity.
Andrew Wei, MBBS, PhD, FRACP, FRCPA, is the head of leukemia research at Alfred Hospital and an adjunct senior lecturer at Monash University in Melbourne, Australia. He is also chief investigator for national cooperative group clinical studies via the Australasian Leukaemia and Lymphoma Group, for which he is the chair for the AML disease group.
He completed his medical training in clinical and laboratory haematology at the University of Melbourne, Mellbourne, Australia. He then moved to the Walter & Eliza Hall Institute for Medical Research, Mellbourne, Australia, where he was awarded a Leukaemia Foundation of Australia clinical scholarship to study oncogene co-operation in acute leukaemia, for which he was awarded the Baikie Award for his research.
Dr Wei conducts clinical and translational AML research, with a focus on novel and targeted therapies. His impressive doctoral studies contributed to discoveries elucidating the functional interaction between pro-apoptotic BH3 and pro-survival BCL-2 family members, the importance of Mcl-1 for the BH3 mimetic ABT-737 and the pro-survival function of the EBV BCL-2 homologue BHRF-1.
Alan Burnett, MD, PhD, is a professor and head of the Department of Haematology at the University of Wales College of Medicine, Cardiff, UK.
Prof Burnett trained at Glasgow University in the UK and undertook postgraduate research at the Ben May Laboratory for Cancer Research, University of Chicago, IL, USA. He returned to Glasgow to establish the Stem Cell Program and pioneered the first CR1 autografts in acute myeloid leukemia.
In 2002, the National Cancer Research Institute was established in the UK where he was appointed chair of the National Cancer Research Institute Haematological Oncology Study Group. He has served on several advisory committees and is past president of the British Society of Haematology and chair of the UK National Training Program.
Jorge Cortes, MD, is deputy chair and professor of medicine in the Department of Leukemia at MD Anderson Cancer Center, where he directs the CML and AML programs.
Dr Cortes studied medicine at the National Autonomous University of Mexico along with postgraduate training at The National Institute of Medical Sciences and Nutrition Salvador Zubirán. He soon completed hematology/oncology fellowships at the University of Texas Health Science and MD Anderson Cancer Centers.
His work focuses on the new drug development and the management of patients with myelodysplatic syndromes, acute and chronic leukemias, and myeloproliferative disorders. He is editor-in-chief of Clinical Leukemia and Current Malignant Hematology Reports. In addition, Dr Cortes serves on the Board of Directors for The Leukemia & Lymphoma Society.
He has received numerous awards including the Faculty Scholar Award from MD Anderson in 2003, the Annual Celgene Young Investigator Achievement Award for Clinical Research in Hematology in 2005, The Dr John J. Kenny Award from The Leukemia & Lymphoma Society in 2007, the Otis W. and Pearl L. Walters Faculty Achievement Award in Clincial Research from MD Anderson in 2007.
Wolfgang Hiddemann, MD, PhD, is a professor at the Ludwig Maximilian University of Munich, Munich, Germany.
Prof Hiddemann studied medicine at the Universities of Bonn and Münster in Germany and undertook postgraduate research at the Memorial Sloan-Kettering Cancer Center in New York. Since 1998, he has been the director of the Department of Internal Medicine III at the University of Munich Hospital.
His work is primarily concerned with the pathogenesis and therapy of ALL and AML. He is on the editorial board of several journals, including Annals of Oncology, The Internist, German Medical Weekly and Leukemia. In addition, he is a member of various professional societies, such as the German Society of Hematology and Medical Oncology and the Foundation German Cancer Aid.
Miguel Sanz, MD, is head of the Department of Hematology and Bone Marrow Transplant Unit at the University Hospital La Fe in Valencia, Spain, and professor of medicine at the University of Valencia.
He received his MD at University of Salamanca in Spain and subsequently completed his residency and fellowship in Hematology at the Universtiy Hospital La Fe. After earning his medical degree at the University of Salamanca in Spain, he was intern, resident and subsequently completed a fellowship in Hematology at the University Hospital La Fe, where he was eventually appointed head of the Hematology Department in 2007. Prof Sanz is chairman of the Spanish PETHEMA Group and leads the working parties of acute promyelocytic leukemia, AML and infections in neutropenic patients.